Editorial

You have full text access to this OnlineOpen article

An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!†‡

  1. Angel Rubin1,2,
  2. Marina Berenguer1,2,§,*

Article first published online: 28 APR 2010

DOI: 10.1002/lt.22090

Issue

Liver Transplantation

Liver Transplantation

Volume 16, Issue 6, pages 697–700, June 2010

Additional Information

How to Cite

Rubin, A. and Berenguer, M. (2010), An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!. Liver Transpl, 16: 697–700. doi: 10.1002/lt.22090

Author Information

  1. 1

    Hepatogastroenterology Service, Valencia, Spain

  2. 2

    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Valencia, Spain

  1. §

    Telephone: 011-34-96-386-8792; FAX: 011-34-96-398-7333

*Hepatogastroenterology Service, Avenida Campanar no 21, Valencia, 46009 Spain

  1. †

    See Article on Page 748

  2. ‡

    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas is funded by the Instituto de Salud Carlos III.

Publication History

  1. Issue published online: 25 MAY 2010
  2. Article first published online: 28 APR 2010
  3. Accepted manuscript online: 28 APR 2010 12:00AM EST
  4. Manuscript Accepted: 19 APR 2010
  5. Manuscript Received: 9 APR 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (70K)

REFERENCES

  • 1
    Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-115.
    Direct Link:
  • 2
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
    Direct Link:
  • 3
    Inadomi JM. Decision analysis and economic modelling: a primer. Eur J Gastroenterol Hepatol 2004; 16: 535-542.
  • 4
    Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 28( suppl 1): 74-81.
    Direct Link:
  • 5
    Bala M, Mauskopf J. Optimal assignment of treatments to health state using a Markov decision model: an introduction to basic concepts. Pharmacoeconomics 2006; 24: 345-354.
  • 6
    Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000; 19: 92-109.
  • 7
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G. Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
    Direct Link:
  • 8
    Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, Pol S. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
  • 9
    Carrión JA, Navas M, García-Retortillo M, García-Pagán JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756.
  • 10
    Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C after liver transplantation. Am J Transplant 2008; 8: 679-687.
    Direct Link:
  • 11
    Picciotto F, Tritto G, Lanza A, Addario L, De Luca M, Di Costanzo G, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465.
  • 12
    Selzner N, Renner EL, Selzner M, Adeyi O, Kasfhi A, Therapondos G, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214-1221.
  • 13
    Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45: 127-143.
  • 14
    Saab S, Hunt D, Stone M, Tong M. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010; 16: 748-759.
  • 15
    Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, De la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
  • 16
    Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
  • 17
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
  • 18
    Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738-746.
    Direct Link:
View Full Article (HTML) Get PDF (70K)